Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. Pietrantonio F, et al. Among authors: iacovelli r. Target Oncol. 2016 Jun;11(3):337-43. doi: 10.1007/s11523-015-0397-2. Target Oncol. 2016. PMID: 26538496
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A. Procopio G, et al. Among authors: iacovelli r. Future Oncol. 2014 Aug;10(10):1741-50. doi: 10.2217/fon.14.48. Epub 2014 Mar 18. Future Oncol. 2014. PMID: 24641206
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.
Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli R, Miceli R, Bossi I, Leone G, Milione M, Pelosi G, de Braud F. Pietrantonio F, et al. Among authors: iacovelli r. PLoS One. 2014 Apr 1;9(4):e92147. doi: 10.1371/journal.pone.0092147. eCollection 2014. PLoS One. 2014. PMID: 24691006 Free PMC article.
Targeted treatments in advanced renal cell carcinoma: focus on axitinib.
Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G. Verzoni E, et al. Among authors: iacovelli r. Pharmgenomics Pers Med. 2014 Mar 27;7:107-16. doi: 10.2147/PGPM.S37098. eCollection 2014. Pharmgenomics Pers Med. 2014. PMID: 24715765 Free PMC article. Review.
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.
Pietrantonio F, Maggi C, Fanetti G, Iacovelli R, Di Bartolomeo M, Ricchini F, Deraco M, Perrone F, Baratti D, Kusamura S, Tamborini E, Castano A, Consonni PV, Bossi I, Gavazzi C, Milione M, Pelosi G, de Braud F. Pietrantonio F, et al. Among authors: iacovelli r. Oncologist. 2014 Aug;19(8):845-50. doi: 10.1634/theoncologist.2014-0106. Epub 2014 Jun 20. Oncologist. 2014. PMID: 24951608 Free PMC article.
244 results